NLS Pharmaceutics Ltd. -CW25NLSPWPreferred / convertible
13F holders, Q2 2024 (June 30)6holders
1new positions
1sold out
1famous investor
$0.03avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding NLS Pharmaceutics Ltd. -CW25 (NLSPW) in their 13F filings, unchanged from Q1 2024. 1 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($17K), Altium Capital Management LLC ($7K) and Hudson Bay Capital Management LP ($3K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- NLS Pharmaceutics Ltd. -CW25
- CUSIP
- H57830111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $482 |
| Exits | 1 | $295 |
All 13F filers, Q1 2024 → Q2 2024: 16,008 shares bought and 6,656 shares sold, net +9,352 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Armistice Capital, LLC | — | No change | 500,000 | $17K |
| Altium Capital Management LLC | — | No change | 200,000 | $7K |
| Hudson Bay Capital Management LP | — | No change | 100,000 | $3K |
| Citadel Advisors | — | New | 16,008 | $482 |
| Susquehanna International Group, LLP | — | Reduce -2.6% | 12,221 | $368 |
| Clear Street LLC | — | Reduce -3.6% | 8,271 | $285 |
"% of holder's portfolio" is NLSPW's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. -CW25 the manager owns.